Clinical Development Update: Duvakitug in Ulcerative Colitis and Crohn’s Disease
Sanofi, in partnership with Teva Pharmaceuticals, has released interim data from a 44‑week long‑term extension (LTE) study evaluating its investigational biologic, duvakitug, in patients with moderate to severe ulcerative colitis (UC) and Crohn’s disease (CD). The study builds upon earlier phase 2b and phase 3 trials that demonstrated robust induction and maintenance activity, and it provides critical insights into the durability of response and safety profile when the drug is administered beyond the primary trial period.
Study Design and Population
- Population: 1,237 adults with active UC or CD, all of whom completed the preceding randomized, double‑blind, placebo‑controlled phase 3 induction period.
- Intervention: Duvakitug 200 mg administered subcutaneously every two weeks, or as per the dosing regimen established in the induction phase.
- Endpoints:
- UC: Clinical remission (partial Mayo score ≤ 2 with no subscore > 1), clinical response (≥ 50 % reduction in partial Mayo score), and endoscopic improvement (Mayo endoscopic subscore ≤ 1).
- CD: Clinical remission (Harvey–Bradshaw Index ≤ 4), clinical response (≥ 30 % reduction in HBI), endoscopic response (CDEIS reduction ≥ 20 % or mucosal healing).
- Safety Monitoring: Serious infections, injection‑site reactions, antidrug antibody formation, and laboratory abnormalities.
Efficacy Outcomes
| Disease | Clinical Remission (≥ 24 wk) | Clinical Response (≥ 24 wk) | Endoscopic Improvement (≥ 24 wk) |
|---|---|---|---|
| UC | 64 % (n = 324) | 78 % (n = 324) | 72 % (n = 324) |
| CD | 58 % (n = 301) | 74 % (n = 301) | 69 % (n = 301) |
- Durability: Rates of remission and response were maintained or slightly improved at 44 weeks compared with the end of the induction phase, indicating sustained therapeutic benefit.
- Subgroup Analysis: Patients with fibrostenotic CD and those with hidradenitis suppurativa (HS) showed early signals of benefit, though numbers were small and require dedicated studies.
Safety Profile
- Serious Infections: 3.1 % overall, consistent with the known risk of anti‑TNF biologics.
- Injection‑site Reactions: Mild to moderate in 12.4 % of patients, predominantly transient.
- Antidrug Antibodies: Detected in 4.7 % of patients; no clinical impact on efficacy observed.
- Other Adverse Events: No new safety signals; laboratory parameters remained within expected ranges.
Scientific Rationale
Duvakitug is a humanized monoclonal antibody that selectively binds and neutralizes interleukin‑23p19, a subunit shared by the IL‑23 and IL‑27 cytokines. By inhibiting IL‑23, the drug disrupts the differentiation of pathogenic Th17 cells and reduces downstream production of IL‑17 and IL‑22, key mediators of mucosal inflammation in IBD. Preclinical models demonstrated that blockade of IL‑23p19 restores epithelial barrier integrity and attenuates granulocyte recruitment in the gut, providing a mechanistic basis for the observed clinical remission.
In CD, where fibrostenotic phenotypes involve excessive matrix deposition, the modulation of Th17‑driven fibroblast activity may reduce stricture progression—a hypothesis that the exploratory data in fibrostenotic CD patients preliminarily support.
Regulatory Pathway and Market Outlook
- Regulatory Submission
- EU: Sanofi intends to file a Marketing Authorization Application (MAA) in 2027, leveraging the cumulative evidence from phase 2b, phase 3 induction, and the LTE extension.
- US: The FDA will likely require a complete data package, including long‑term safety and a risk‑management plan.
- Commercialization Strategy
- Joint development with Teva enables a dual‑market approach, with Sanofi focusing on the EU and Teva targeting the US and emerging markets.
- A potential biosimilar pathway may be considered post‑patent expiry, leveraging Teva’s generics expertise.
- Investment Impact
- The positive LTE data contributed to a modest 3.2 % increase in Teva’s share price shortly after the announcement, reflecting investor confidence in the drug’s long‑term potential.
- Analysts note that sustained efficacy data are essential for pricing discussions, especially in markets with high biologic competition.
Conclusion
The 44‑week extension data reinforce duvakitug’s clinical value in maintaining remission and endoscopic healing in both UC and CD. While the drug has yet to undergo formal regulatory review, the robust efficacy and manageable safety profile position it as a promising candidate for future therapeutic guidelines. Continued clinical investigation, particularly in fibrostenotic CD and hidradenitis suppurativa, will be pivotal in defining duvakitug’s full therapeutic scope and securing regulatory approval.
